Hummingbird Bioscience to present data on HMBD-002-V4 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Hummingbird Bioscience to present data on HMBD-002-V4 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Hummingbird Bioscience, a systems biology powered drug discovery and development company focused on novel cancer therapeutics, will present a poster “HMBD-002-V4: A novel anti-VISTA antibody that uniquely neutralizes VISTA activity and potently inhibits tumor growth by remodeling an immunosuppressive tumor microenvironment” at the Society for Immunotherapy of Cancer Annual Meeting taking place in Washington D.C. on November 9-11, 2018.

HMBD-002-V4 is a novel anti-VISTA antibody developed using Hummingbird’s proprietary Rational Antibody Discovery platform to block a species-conserved functional domain on the VISTA protein to neutralize VISTA signaling, while maintaining binding to the rodent and cyno versions of the protein allowing the antibody to be tested in animal models.

VISTA is a negative checkpoint regulator of the immune system and is highly expressed on Myeloid Derived Suppressor Cells (MDSCs), a leading cause of immunotherapy resistance. VISTA expressing MDSC are frequently upregulated in tumors following anti-PD(L)1 or anti-CTLA4 checkpoint therapy, leading to immune suppression and poor patient responses to therapy. However, VISTA is also expressed to a lesser extent on other myeloid cells such as dendritic cells, and some T-cells. No other therapy has been able to neutralize VISTA signaling on MDSCs while avoiding depletion of other VISTA expressing cells.

HMBD-002-V4 has demonstrated the ability to neutralize VISTA signaling in cell models and release suppression of the immune system. In tumor models, treatment with HMBD-002-V4 potently inhibited the growth of a variety of MDSC-high tumors without depletion of VISTA expressing cells. HMBD-002-V4 also synergised with anti-PD(L)1 therapy to counteract the expansion of MDSCs and was shown able to remodel an immunosuppressive tumor microenvironment towards a pro-inflammatory environment. HMBD-002-V4 has also been shown to be safe in animal studies.

HMBD-002-V4 is wholly owned and developed by Hummingbird Bioscience.

For further information please email

About Hummingbird Bioscience

Hummingbird Bioscience is an innovative biotechnology company, harnessing the potential of integrative biology to discover and develop novel cancer immuno-therapeutics. We are focused on taking projects from validated target to clinical proof of concept. Our data and model driven integrative biology approach provide an unprecedented ability to understand and manipulate the immune system – allowing us to 1) Identify the right targets and mechanisms 2) Generate best in class antibodies against these targets 3) Characterize the effect of our drug candidates on the tumor and immune system at a molecular and cellular level, to better predict clinical outcomes of our drugs. We have compelling pre-clinical data for four potential first in class therapeutic programs focused on the most exciting targets in oncology.

Leave a Reply